Swedish Firm Taps Biomodels for Predictive HSCT Study | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biomodels said today that Swedish Orphan Biovitrum has contracted it to test the possibility of developing a predictive assay to determine which stem cell therapy patients may be at risk for a complication called oral mucositis.

Under the agreement, the Watertown, Mass.-based preclinical drug research firm aims to develop a screening platform to define mucositis risk for patients undergoing conditioning regimens for hematopoietic stem cell transplants (HSCT).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.